Charles River Laboratories International, Inc. (NYSE:CRL) Stock Holdings Increased by Guggenheim Capital LLC

Guggenheim Capital LLC grew its position in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 9.6% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 8,253 shares of the medical research company’s stock after buying an additional 725 shares during the quarter. Guggenheim Capital LLC’s holdings in Charles River Laboratories International were worth $1,524,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Versant Capital Management Inc lifted its stake in Charles River Laboratories International by 1,071.4% during the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after purchasing an additional 150 shares during the last quarter. Pinnacle Bancorp Inc. lifted its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares during the last quarter. Pilgrim Partners Asia Pte Ltd acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at about $48,000. Tortoise Investment Management LLC grew its position in shares of Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company’s stock valued at $49,000 after buying an additional 115 shares during the last quarter. Finally, Huntington National Bank raised its stake in Charles River Laboratories International by 120.6% during the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company’s stock worth $55,000 after acquiring an additional 164 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 3.2 %

Shares of CRL stock opened at $102.70 on Tuesday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41. The stock has a market cap of $5.04 billion, a PE ratio of 684.67, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The business’s fifty day moving average is $150.04 and its 200-day moving average is $173.14. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $254.15.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The firm had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same period in the previous year, the business earned $2.46 earnings per share. Charles River Laboratories International’s revenue for the quarter was down 1.1% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Activity at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of Charles River Laboratories International stock in a transaction on Thursday, February 20th. The stock was bought at an average cost of $164.63 per share, with a total value of $249,249.82. Following the completion of the purchase, the chief operating officer now owns 55,058 shares of the company’s stock, valued at $9,064,198.54. This represents a 2.83 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Joseph W. Laplume sold 4,400 shares of the firm’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the completion of the transaction, the executive vice president now owns 20,013 shares of the company’s stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

CRL has been the subject of a number of research reports. William Blair downgraded Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Robert W. Baird lowered their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating for the company in a research note on Thursday, February 20th. UBS Group reiterated a “neutral” rating and issued a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Barclays lowered their price target on shares of Charles River Laboratories International from $160.00 to $145.00 and set an “equal weight” rating for the company in a research report on Thursday, April 10th. Finally, Redburn Atlantic upgraded shares of Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. One equities research analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $182.00.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).